NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH | Biotech Hunter

Enrollment

183

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

May 10, 2025

Study Completion Date

June 10, 2025

Conditions

Non-alcoholic Fatty Liver DiseaseNon-alcoholic Steatohepatitis

Interventions

DRUG

2mg of ASC41

ASC41 tablet administered orally once daily.

DRUG

4mg of ASC41 (2 tablets of 2 mg ASC41)

ASC41 tablets administered orally once daily.

DRUG

Placebo

Placebo tablets administered orally once daily.

Trial Locations (1)

The affiliated Hospital of Hangzhou Normal University, Hangzhou